IDIOPATHIC PULMONARY FIBROSIS (IPF) MTX-463-I201
ELIGIBILITY & REQUIREMENTS
- Aged 40 or older
- Confirmed diagnosis of Idiopathic Pulmonary Fibrosis (IPF)
WHAT'S INVOLVED
- The trial will run for approximately 32 weeks
- Nine clinic visits to the Institute for Respiratory Health in Midland
- Health check by our doctors and nurses
STUDY OUTLINE
This international research study will test infusing MTX-463, an investigational drug.
MTX-463 is a monoclonal antibody In this research study, you will get either MTX-463-I201 or placebo.
To find out if this trial is suitable for you, please register below, or contact our Clinical Trials Team on 6151 0813 or email clinicaltrials@resphealth.uwa.edu.au
PRINCIPAL INVESTIGATOR
Dr David Manners (Midland)